Navigation Links
Study Suggests Way to 'Mop Up' Leukemia Cells
Date:1/8/2010

Vaccine beats back cancer left behind after treatment, researchers say,,,,

FRIDAY, Jan. 8 (HealthDay News) -- Preliminary research suggests that a vaccine could help reduce the risk of a relapse in some people who take the drug Gleevec to treat chronic myeloid leukemia.

"Should this vaccine approach prove to be successful, the ability to get patients off lifelong Gleevec therapy would be a significant advance," Dr. Hyam Levitsky, a professor of oncology, medicine and urology at the Johns Hopkins Kimmel Cancer Center in Baltimore, said in a news release from the center.

Imatinib mesylate (Gleevec) treats chronic myeloid leukemia, but can leave some cancerous cells behind. They can cause a relapse.

Researchers from the cancer center tested a vaccine on 19 people who had cancerous cells even though they'd taken Gleevec for a year. After about 72 months, the number of cancer cells had declined in 13 people. In seven, the cancer had vanished. Reported side effects of the treatment were relatively rare.

But it's not clear if the results were actually caused by the vaccine, the researchers said, because of the small number of participants and the lack of comparison with other treatments.

"We want to get rid of every last cancer cell in the body," Levitsky said, "and using cancer vaccines may be a good way to mop up residual disease."

The vaccine was made from cancer cells that were blasted with radiation to stop them from being cancerous, the researchers said.

The research, funded by the U.S. National Institutes of Health, was published in the Jan. 1 issue of Clinical Cancer Research.

More information

The U.S. National Cancer Institute has more on Gleevec.



-- Randy Dotinga



SOURCE: Johns Hopkins Kimmel Cancer Center, news release, Jan. 6, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Periodic Paralysis Study Reveals Gene Causing Disorder
2. UCLA study shows metformin is safe for patients with advanced heart failure and diabetes mellitus
3. Technology new gateway into treatment for problem alcohol users: Study
4. Few breast cancer surgeons follow quality of care standards, U-M study finds
5. Study shows serious emotional disturbances among children after Katrina
6. Study links restless leg syndrome with erectile dysfunction in older men
7. Study identifies those elderly most at risk for major depression
8. Despite Earlier Doubts, Feinstein Study Shows Fetal Transplants May Benefit Parkinson's Patients Over Age 60
9. New Study Shows That American Public is Willing to Accept Major Reforms in Medicare Program
10. Herbal Science Organization Clarifies New Ginkgo Study
11. CRN Responds to Ginkgo Biloba Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... , ... August 18, 2017 , ... The Golseth Agency, ... the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide support ... In early June of this year, Christina and her children returned from out of ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... highly trained practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has ... imbalance and conditions of aging, such as menopause, andropause, thyroid disorder and adrenal ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage ... up its marketing efforts with its product now available through Jet.com. , After ... public. The effervescent powdered drink is designed to quickly detox the body thereby avoiding ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... numbers and call tracking and monitoring solutions, announced today the launch of a ... include a modern navigation and aesthetic, fully responsive design, and an enhanced search ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery about ... Winters. Diane is from Southwest Nebraska where she was raised on a farm. ... The story is fictional, but the friendships and mantra of ‘neighbors helping neighbors’ ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... -- Axium Pharmaceuticals Inc., the creator of the drug Truveta for ... of an IPO. The United States ... of a prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... staggering figure is the fact that Americans spent $42 billion on anxiety ...
(Date:8/14/2017)... Israel , Aug. 15, 2017  BrainStorm ... adult stem cell technologies for neurodegenerative diseases, announced financial ... "We are in ... 3 trial to investigate NurOwn ® in ALS," ... Officer of BrainStorm. "We have agreements with Mass. General ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology: